Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab
{{output}}
Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy remains the standard of care for patients with nonmetastatic muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin. However, many patients cannot receive cisplatin bec... ...
